Ferah Comert Onder

Speaker for pharma conferences Europe-Ferah Comert Onder

Title: Design and Synthesis of New EF2K Inhibitors for The Treatment of TNBC and Pancreatic Cancers and their in vitro release studies from biocompatible natural polymeric particles

Ferah Comert Onder

Canakkale Onsekiz Mart University, Turkey

Biography

Mrs. Cömert Önder graduated as BSc&MSc in Chemistry in 2012 and PhD is still continuning at Science Faculty, Çanakkale Onsekiz Mart University under Supervision of Dr. Mehmet AY. Experienced 3 months Lab. training  at Wolverhampton University in UK, 2011. She is going on research activities in Dr AY's Natural Products and Drug Research Lab., focusing on developing new  prodrug and drug molecules for Cancer Therapy.

Abstract

''Triple-negative” breast cancer (TNBC) and pancreatic cancers are aggressive malignancies that respond poorly to treatments and is associated with high rates patient deaths despite surgery and adjuvant chemotherapy. With the currently available chemotherapeutics 5-survival rates of TNBC is 30 % and pancreatic cancer 1-2 % (with median survival only 6 months). Thus, identification of common and clinically significant molecular targets would help developing targeted therapies for these patients. Recently, potent EF2K inhibitors were tested in vitro and in vivo (mice models) of TNBC and panc cancer models using siRNA or microRNA based gene silencing strategy. There is clearly an urgent need to identify better eEF2K inhibitors to target in various cancers. For this purpose, we designed potent new EF2K inhibitors using computational chemistry techniques and synthesized substituted chromene carboxamide derivatives were confirmed by melting point, FT-IR, 1H-NMR, 13C-NMR, LC-MS spectral analysis. Furthermore, in vitro release studies of these inhibitors were carried out from biocompatible microgels particles with different size ranges (50 nm -500 μm) that prepared from natural polymers such as hyaluronic acid and/or and polymeric sucrose particles.

Audience will learn:
•highlight the importance of protein kinases in the cancer therapy
•how to design potent new inhibitors and approach to their synthesis and using of drug delivery systems
•design new projects with collaboration for cancer therapy